Study shows crinecerfont aids patients with congenital adrenal hyperplasia

Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with congenital adrenal hyperplasia (CAH), according to a study published June 2 in the New England Journal of Medicine to coincide with the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston. Richard J. Auchus, M.D., Ph.D., from the University of Michigan Medical School in Ann Arbor, and colleagues randomly assigned adults with CAH to receive crinecerfont or placebo for 24 weeks in a 2:1 ratio (122 and 60 Read More

Related posts:

  1. Acupuncture aids sleep in patients with Parkinson disease
  2. Study shows 13% of patients with dementia may instead have cognitive decline from cirrhosis
  3. Psoriasis study shows high level of arthritis symptoms in patients
  4. Clinical study shows zebrafish avatars of cancer patients have high predictive power
  5. Pilot study shows promise for remote cognitive rehabilitation for multiple sclerosis patients
  6. New genetic markers for adrenal cancer may predict survival
  7. Aquablation, HoLEP may provide unique benefits for men with benign prostate hyperplasia
  8. Neurobiologists reveal secret of congenital central hypoventilation syndrome

Leave a Reply

Your email address will not be published. Required fields are marked *